FAERS

April 13, 2018April 13, 2018

Acute Acalculous Cholecystitis Linked to Lemtrada Use in RRMS Patients, FDA Reports

News

Acute acalculous cholecystitis (AAC) is a rare but potentially life-threatening adverse effect linked to treatment with Lemtrada (alemtuzumab) in patients with relapsing-remitting multiple sclerosis (RRMS), according to ... Read more

June 30, 2017July 2, 2017

Link Between MS Therapy Tysabri and Melanoma Possible, an Adverse Reactions Watchdog Group Says

News

The multiple sclerosis therapy Tysabri could trigger melanoma, the Southern Network on Adverse Reactions (SONAR) has warned. Although its investigation failed to demonstrate that melanoma is more ... Read more

February 1, 2017February 1, 2017

Tecfidera Use Linked to Liver Injury in MS Patients, but Severe Injury Appears Rare

News

Tecfidera (dimethyl fumarate or DMF) use by multiple sclerosis (MS) patients can result in liver injury and, in rare cases, even severe injury, a study found, leading its ... Read more

Pin It on Pinterest